<DOC>
	<DOC>NCT02327546</DOC>
	<brief_summary>The primary purpose of this study is to assess the single-dose bioavailability of AKB-6548 with ferrous sulfate relative to AKB-6548 in healthy volunteers.</brief_summary>
	<brief_title>Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548</brief_title>
	<detailed_description />
	<criteria>Healthy male subjects 18 to 55 years of age with a body mass index between 18 and 30 kg/m2 Participants and their partners must use a highly effective form of contraception during the study and for 1 month following discharge from the Clinical Research Unit (CRU) Subjects must discontinue all iron preparations for 14 days prior to study drug administration Current or past history of cardiovascular, cerebrovascular, pulmonary, renal or liver disease Positive serology results for HBsAg, HCV, and HIV at Screening Renal impairment (estimated glomerular filtration rate (eGFR) of &lt;65mL/min) Known active cancer (except nonmelanoma skin cancer) or history of chemotherapy use within the previous 24 months Current or past history of gastric or duodenal ulcers or other diseases of the GI tract (including gastric bypass surgeries) that could interfere with absorption of study drug Subjects with a known history of smoking and/or have used nicotine or nicotinecontaining products within the past 6 months</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Anemia</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>Chronic renal insufficiency</keyword>
	<keyword>Renal impairment</keyword>
	<keyword>Ferrous sulfate</keyword>
	<keyword>Iron</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>End stage renal disease</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Oral anemia treatment</keyword>
	<keyword>Hypoxia-induciable factor</keyword>
	<keyword>HIF</keyword>
	<keyword>Hypoxia-induciable factor prolyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
</DOC>